NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis $0.04 0.00 (-8.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.04 +0.00 (+1.02%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NuCana Stock (NASDAQ:NCNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NuCana alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.1752-Week Range$0.03▼$10.79Volume121.28 million shsAverage Volume201.83 million shsMarket Capitalization$237.73 thousandP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingModerate Buy Company Overview NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. Read More NuCana Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreNCNA MarketRank™: NuCana scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNuCana has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNuCana has received no research coverage in the past 90 days.Read more about NuCana's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NuCana are expected to grow in the coming year, from ($13.42) to ($10.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NuCana's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted478.95% of the outstanding shares of NuCana have been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently increased by 542.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted478.95% of the outstanding shares of NuCana have been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently increased by 542.83%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment-0.33 News SentimentNuCana has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NuCana this week, compared to 1 article on an average week.Search Interest52 people have searched for NCNA on MarketBeat in the last 30 days. This is an increase of 49% compared to the previous 30 days.MarketBeat Follows26 people have added NuCana to their MarketBeat watchlist in the last 30 days. This is an increase of 24% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NuCana's insider trading history. Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address NCNA Stock News HeadlinesNuCana Announces ADS Ratio ChangeAugust 1 at 4:17 PM | globenewswire.comNuCana Stock Set to Reverse Split on Friday, August 8th (NASDAQ:NCNA)July 27, 2025 | americanbankingnews.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)NuCana plc: NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM ExecutionJuly 21, 2025 | finanznachrichten.deNuCana Cancels All Outstanding Series A Warrants Following Strategic ATM ExecutionJuly 21, 2025 | globenewswire.comNuCana plc (NCNA) Latest Stock News & Headlines - Yahoo FinanceJuly 13, 2025 | finance.yahoo.comNCNA - NuCana PLC ADR Price vs Fair Value | MorningstarJuly 11, 2025 | morningstar.comMNuCana Announces Plan to Implement ADS Ratio ChangeJuly 11, 2025 | globenewswire.comSee More Headlines NCNA Stock Analysis - Frequently Asked Questions How have NCNA shares performed this year? NuCana's stock was trading at $1.19 at the start of the year. Since then, NCNA stock has decreased by 96.7% and is now trading at $0.0391. How were NuCana's earnings last quarter? NuCana PLC Sponsored ADR (NASDAQ:NCNA) issued its quarterly earnings results on Monday, June, 2nd. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.62. When did NuCana's stock split? NuCana's stock reverse split on the morning of Friday, August 8th 2025.The 1-200 reverse split was announced on Friday, July 11th 2025. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did NuCana IPO? NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Plug Power (PLUG), SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings6/02/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NCNA CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for NuCana$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+63,838.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($7.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.28 million Net MarginsN/A Pretax MarginN/A Return on Equity-319.85% Return on Assets-88.55% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.03Miscellaneous Outstanding Shares6,080,000Free Float4,181,000Market Cap$237.73 thousand OptionableNot Optionable Beta1.41 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:NCNA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.